Amerikanische Gesellschaft für Hirudotherapie

Neurocoagulation from a Mechanistic Point of View in the Central Nervous System

Review published in Seminars in thrombosis and hemostasis (2022)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungShavit-Stein E et al. · Seminars in thrombosis and hemostasis, 2022

Abstract

Coagulation mechanisms are critical for maintaining homeostasis in the central nervous system (CNS). Thrombin, an important player of the coagulation cascade, activates protease activator receptors (PARs), members of the G-protein coupled receptor family. PAR1 is located on neurons and glia. Following thrombin activation, PAR1 signals through the extracellular signal-regulated kinase pathway, causing alterations in neuronal glutamate release and astrocytic morphological changes. Similarly, the anticoagulation factor activated protein C (aPC) can cleave PAR1, following interaction with the endothelial protein C receptor. Both thrombin and aPC are expressed on endothelial cells and pericytes in the blood-brain barrier (BBB). Thrombin-induced PAR1 activation increases cytosolic Ca2+ concentration in brain vessels, resulting in nitric oxide release and increasing F-actin stress fibers, damaging BBB integrity. aPC also induces PAR1 activation and preserves BBB vascular integrity via coupling to sphingosine 1 phosphate receptors. Thrombin-induced PAR1 overactivation and BBB disruption are evident in CNS pathologies. During epileptic seizures, BBB disruption promotes thrombin penetration. Thrombin induces PAR1 activation and potentiates N-methyl-D-aspartate receptors, inducing glutamate-mediated hyperexcitability. Specific PAR1 inhibition decreases status epilepticus severity in vivo. In stroke, the elevation of brain thrombin levels further compromises BBB integrity, with direct parenchymal damage, while systemic factor Xa inhibition improves neurological outcomes. In multiple sclerosis (MS), brain thrombin inhibitory capacity correlates with clinical presentation. Both thrombin inhibition by hirudin and the use of recombinant aPC improve disease severity in an MS animal model. This review presents the mechanisms underlying the effects of coagulation on the physiology and pathophysiology of the CNS.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsBlood-Brain BarrierEndothelial CellsGlutamic AcidHumansReceptor, PAR-1Thrombin

Zusammenfassung

Coagulation mechanisms are critical for maintaining homeostasis in the central nervous system (CNS).

Warum dies für die Hirudotherapie relevant ist

This review examines how coagulation proteases—particularly thrombin and activated protein C—influence central nervous system physiology and pathophysiology through protease-activated receptor-1 (PAR1) signaling, with relevance to epilepsy, stroke, and multiple sclerosis. The abstract reports that thrombin inhibition by hirudin, along with recombinant activated protein C, improved disease severity in a multiple sclerosis animal model, situating this finding within ASH's domain of thrombin-modulating agents. The key caveat is that this is a review (per publication types) drawing on preclinical animal evidence; the hirudin observation is one finding among many, with no clinical data, no direct hirudotherapy application, and no mention of leeches anywhere in the abstract.

Zitation

Neurocoagulation from a Mechanistic Point of View in the Central Nervous System

Shavit-Stein E et al. · Seminars in thrombosis and hemostasis, 2022

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.